You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

invega hafyera Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Invega Hafyera, and what generic alternatives are available?

Invega Hafyera is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has forty-eight patent family members in nineteen countries.

The generic ingredient in INVEGA HAFYERA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Invega Hafyera

A generic version of invega hafyera was approved as paliperidone palmitate by TEVA PHARMS USA on July 6th, 2021.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for invega hafyera?
  • What are the global sales for invega hafyera?
  • What is Average Wholesale Price for invega hafyera?
Summary for invega hafyera
International Patents:48
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 50
Patent Applications: 133
Drug Prices: Drug price information for invega hafyera
What excipients (inactive ingredients) are in invega hafyera?invega hafyera excipients list
DailyMed Link:invega hafyera at DailyMed
Drug patent expirations by year for invega hafyera
Drug Prices for invega hafyera

See drug prices for invega hafyera

Pharmacology for invega hafyera

US Patents and Regulatory Information for invega hafyera

invega hafyera is protected by three US patents and one FDA Regulatory Exclusivity.

Patents protecting invega hafyera

Dosing regimens associated with extended release paliperidone injectable formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE

Dosing regimens associated with extended release paliperidone injectable formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA BY ADMINISTRATION OF A SIX-MONTH PALIPERIDONE PALMITATE INJECTABLE SUSPENSION FILLED SYRINGE THAT HAS BEEN SHIPPED AND STORED IN A HORIZONAL POSITION

FDA Regulatory Exclusivity protecting invega hafyera

NEW STRENGTH
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVEGA HAFYERA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207946-005 Aug 30, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms INVEGA HAFYERA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207946-006 Aug 30, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms INVEGA HAFYERA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207946-005 Aug 30, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for invega hafyera

See the table below for patents covering invega hafyera around the world.

Country Patent Number Title Estimated Expiration
China 116583270 与延长释放帕潘立酮可注射制剂相关的给药方案 (Dosing regimens associated with extended release paliperidone injectable formulations) ⤷  Sign Up
Germany 122011100027 ⤷  Sign Up
Canada 3203448 SCHEMAS POSOLOGIQUES ASSOCIES A DES FORMULATIONS INJECTABLES DE PALIPERIDONE A LIBERATION PROLONGEE (DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for invega hafyera

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0904081 SPC/GB11/044 United Kingdom ⤷  Sign Up PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0904081 C00904081/01 Switzerland ⤷  Sign Up PRODUCT NAME: PALIPERIDON PALMITATESTER; REGISTRATION NO/DATE: SWISSMEDIC 60466 20101215
0904081 416 Finland ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.